Rhythm Historical Cash Flow
| RYTM Stock | USD 56.12 0.64 1.15% |
Analysis of Rhythm Pharmaceuticals cash flow over time is an excellent tool to project Rhythm Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 9.9 M or Capital Expenditures of 44.6 K as it is a great indicator of Rhythm Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Rhythm Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rhythm Pharmaceuticals is a good buy for the upcoming year.
Rhythm |
About Rhythm Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Rhythm balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Rhythm's non-liquid assets can be easily converted into cash.
Rhythm Pharmaceuticals Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Rhythm Pharmaceuticals value has been used up. For tax purposes Rhythm Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Rhythm Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Rhythm Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Rhythm Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Rhythm Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Rhythm Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.At this time, Rhythm Pharmaceuticals' Total Cashflows From Investing Activities is very stable compared to the past year. As of the 22nd of December 2024, Change To Netincome is likely to grow to about 24.6 M, though Free Cash Flow is likely to grow to (129.4 M).
Rhythm Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Rhythm Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Rhythm Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 12.8M | 38.6M | (41.7M) | 68.4M | (67.6M) | (64.2M) | |
| Free Cash Flow | (126.1M) | (122.2M) | (151.4M) | (177.7M) | (136.2M) | (129.4M) | |
| Change In Working Capital | 5.1M | (5.9M) | 1.9M | (19.7M) | 4.8M | 5.0M | |
| Begin Period Cash Flow | 49.9M | 62.7M | 101.3M | 59.6M | 128.0M | 134.4M | |
| Other Cashflows From Financing Activities | 2.1M | 2.0M | 4.8M | 82.7M | 34.0M | 41.1M | |
| Depreciation | 834K | 690K | 1.2M | 1.7M | 1.8M | 1.8M | |
| Other Non Cash Items | 203K | (234K) | (250K) | 5.9M | 9.4M | 9.9M | |
| Capital Expenditures | 3.4M | 214K | 5.4M | 4.3M | 47K | 44.7K | |
| Total Cash From Operating Activities | (122.8M) | (122.0M) | (146.0M) | (173.4M) | (136.2M) | (129.3M) | |
| Net Income | (140.7M) | (134.0M) | (69.6M) | (181.1M) | (184.7M) | (175.4M) | |
| Total Cash From Financing Activities | 163.5M | 2.0M | 166.5M | 213.8M | 74.4M | 95.7M | |
| End Period Cash Flow | 62.7M | 101.3M | 59.6M | 128.0M | 60.4M | 51.0M | |
| Sale Purchase Of Stock | 163.5M | 2.0M | 166.5M | 141.5M | 162.7M | 119.9M | |
| Investments | (24.6M) | 158.7M | (163.7M) | 32.3M | (69.1M) | (65.6M) | |
| Total Cashflows From Investing Activities | (28.0M) | 158.5M | (62.2M) | 28.0M | 32.2M | 33.8M | |
| Change To Operating Activities | (5.4M) | 551K | (16.4M) | (6.7M) | (6.0M) | (6.3M) | |
| Change To Netincome | 11.9M | 17.2M | 20.6M | 20.4M | 23.4M | 24.6M | |
| Change To Liabilities | 10.5M | (6.4M) | 18.3M | (5.1M) | (5.8M) | (5.5M) | |
| Stock Based Compensation | 11.9M | 17.5M | 20.8M | 19.8M | 32.6M | 34.2M | |
| Other Cashflows From Investing Activities | (24.6M) | 158.7M | 7M | (4M) | (5.7M) | (6.0M) | |
| Cash And Cash Equivalents Changes | 12.8M | 38.6M | (41.7M) | 68.4M | 78.7M | 82.6M | |
| Cash Flows Other Operating | (5.2M) | 551K | (115.3M) | 405K | 364.5K | 382.7K | |
| Issuance Of Capital Stock | 161.4M | 161.7M | 161.7M | 131.1M | 63.0M | 112.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.